these data demonstrate in a population of patients with ischemic heart disease , that q6h dosing with a sustained release procainamide hydrochloride preparation ( procan-sr , parke-davis ) is associated with only a small acceptable variation between maximal and minimal serum procainamide and n-acetylprocainamide concentrations .
C0600311
procainamide
C0699067
procan-sr